# Opus Genetics, Inc.: overview IRD · Nasdaq · CIK 1228627 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ird.md) · [Financials](/companies/ird/financials.md) · [Filings](/companies/ird/filings.md) · [Insiders](/companies/ird/insiders.md) Latest reported revenue: [$755.0k](/filings/0001628280-26-054381.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-054381). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [3,867](/filings/0001140361-25-041547.md) | [4,302 d](/filings/0001140361-26-009247.md) | [4,370](/filings/0001628280-26-034084.md) | [2,882](/filings/0001628280-26-054381.md) | [3,079](/filings/0001140361-25-041547.md) | [3,865 d](/filings/0001140361-26-009247.md) | [2,157](/filings/0001628280-26-034084.md) | [755](/filings/0001628280-26-054381.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(207.1%)](/filings/0001140361-25-041547.md) | [(884.0%) d](/filings/0001140361-26-009247.md) | [(227.2%)](/filings/0001628280-26-034084.md) | [(309.0%)](/filings/0001628280-26-054381.md) | [(269.9%)](/filings/0001140361-25-041547.md) | [(296.3%) d](/filings/0001140361-26-009247.md) | [(665.9%)](/filings/0001628280-26-034084.md) | [(2182.8%)](/filings/0001628280-26-054381.md) | | Net margin | % | [(194.6%)](/filings/0001140361-25-041547.md) | [(816.7%) d](/filings/0001140361-26-009247.md) | [(187.5%)](/filings/0001628280-26-054381.md) | [(257.5%)](/filings/0001628280-26-054381.md) | [(566.9%)](/filings/0001140361-25-041547.md) | [(427.5%) d](/filings/0001140361-26-009247.md) | [(3038.2%)](/filings/0001628280-26-054381.md) | [(1072.6%)](/filings/0001628280-26-054381.md) | | Diluted EPS | $ per share | [(0.29)](/filings/0001140361-25-041547.md) | not reported | [(0.24)](/filings/0001628280-26-034084.md) | [(0.12)](/filings/0001628280-26-054381.md) | [(0.25)](/filings/0001140361-25-041547.md) | not reported | [(0.75)](/filings/0001628280-26-034084.md) | [(0.14)](/filings/0001628280-26-054381.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.6](/filings/0001140361-23-014868.md) | [39.9](/filings/0001140361-24-012399.md) | [19.0](/filings/0001140361-25-011410.md) | [11.0](/filings/0001140361-26-009247.md) | [14.2](/filings/0001140361-26-009247.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(3854.8%)](/filings/0001140361-23-014868.md) | [45.7%](/filings/0001140361-24-012399.md) | [(55.5%)](/filings/0001140361-25-011410.md) | [(564.7%)](/filings/0001140361-26-009247.md) | [(271.9%)](/filings/0001140361-26-009247.md) | | Net margin | % | [(9625.3%)](/filings/0001140361-23-014868.md) | [44.9%](/filings/0001140361-24-012399.md) | [(52.4%)](/filings/0001140361-25-011410.md) | [(523.4%)](/filings/0001140361-26-009247.md) | [(349.3%)](/filings/0001140361-26-009247.md) | | Diluted EPS | $ per share | [(3.82)](/filings/0001140361-23-014868.md) | [0.87](/filings/0001140361-24-012399.md) | [(0.46)](/filings/0001140361-25-011410.md) | [(2.15)](/filings/0001140361-26-009247.md) | [(0.80)](/filings/0001140361-26-009247.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ird/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-23 | [Schachle Joseph K](/insiders/1145914.md) | Chief Operating Officer, Officer | Sale (S) | 4,767 | $3.565 | $17.0k | [Form 4](/filings/0001140361-26-040908.md) | | 2026-10-23 | [Yerxa Benjamin R](/insiders/1145910.md) | President, Director, Officer | Sale (S) | 25,520 | $3.5317 | $90.1k | [Form 4](/filings/0001140361-26-040906.md) | | 2026-10-23 | [Yerxa Benjamin R](/insiders/1145910.md) | President, Director, Officer | Sale (S) | 7,669 | $3.5514 | $27.2k | [Form 4](/filings/0001140361-26-040906.md) | | 2026-10-23 | [Gagnon Robert E.](/insiders/1504983.md) | Chief Financial Officer, Officer | Sale (S) | 14,000 | $3.5464 | $49.6k | [Form 4](/filings/0001140361-26-040896.md) | | 2026-10-23 | [Magrath George](/insiders/1999390.md) | Chief Executive Officer, Director, Officer | Sale (S) | 9,591 | $3.585 | $34.4k | [Form 4](/filings/0001140361-26-040893.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $25.0m | 6,077,084 | | Added +2,056 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $24.8m | 6,029,775 | | Unchanged | | [BIOS Capital Management, LP](/funds/1813845.md) | 2026-06-30 | $15.1m | 3,683,429 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $12.8m | 3,116,487 | | Added +2,968,747 | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $12.7m | 3,087,866 | | Added +369,837 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $12.6m | 3,061,359 | | Added +1,380,029 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $12.6m | 3,061,359 | | Added +1,380,029 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $12.2m | 2,958,683 | | Added +508,696 | | [Boxer Capital Management, LLC](/funds/2018299.md) | 2026-06-30 | $11.6m | 2,815,000 | | Added +565,000 | | [Trails Edge Capital Partners, LP](/funds/2077247.md) | 2026-06-30 | $11.3m | 2,743,658 | | Added +2,243,658 | ## Recent filings [All 910 filings](/companies/ird/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-21 | 16:05 ET | [8-K](/filings/0001140361-26-040377.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001140361-26-040377 | | 2026-10-15 | 17:23 ET | [8-K](/filings/0001140361-26-039781.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-039781 | | 2026-09-11 | 07:48 ET | [8-K](/filings/0001140361-26-036277.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-036277 | | 2026-09-09 | 07:30 ET | [8-K](/filings/0001140361-26-035979.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-035979 | | 2026-08-06 | 16:32 ET | [10-Q](/filings/0001628280-26-054381.md) | Quarterly report, period 2026-06-30 | 0001628280-26-054381 | | 2026-08-06 | 07:04 ET | [8-K](/filings/0001628280-26-053824.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-053824 | | 2026-06-16 | 16:11 ET | [8-K](/filings/0001140361-26-025440.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-025440 | | 2026-06-16 | 12:05 ET | [8-K](/filings/0001140361-26-025363.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-025363 | | 2026-05-20 | 19:53 ET | [SCHEDULE 13D/A](/filings/0001193125-26-233062.md) | Ownership report, active investor, amended | 0001193125-26-233062 | | 2026-05-12 | 16:03 ET | [10-Q](/filings/0001628280-26-034084.md) | Quarterly report, period 2026-03-31 | 0001628280-26-034084 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001140361-26-009247.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9fb66ce7-58d9-4cc0-8bb1-cfac20a91ded) ## About the filer - CIK: 1228627 - Tickers: IRD - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:48 ET. No prices; not investment advice.